Recently, CD73 overexpression has been reported in many types of human and mouse cancers, including breast cancer [11, 19], gastric cancer [20], pancreatic cancer [21], colorectal cancer [22, 23], prostate cancer [24] and thyroid cancers [25]. This evidence concerns the gene NT5E and prostate carcinoma.